Varvara Lepchenko has been provisionally suspended under Article 7.12.1 of the 2021 Tennis Anti-Doping Programme (the "Programme"), pending determination of the charge against her at a full hearing pursuant to Article 8 of the Programme.
Ms. Lepchenko, a 35-year-old player from the United States, provided a urine sample on 12 July 2021 in association with her participation in the WTA Hungarian Grand Prix, played in Budapest, Hungary from 12-18 July 2021. That sample was sent to the World Anti-Doping Agency (“WADA”) accredited laboratory in Montreal, Canada for analysis, and was found to contain adrafinil and/or modafinil metabolite. Adrafinil and Modafinil are Non-Specified substances, which are prohibited under category S6 of the 2021 WADA Prohibited List (Stimulants), and therefore also prohibited under the Programme. Positive tests for Non-Specified Substances carry a mandatory Provisional Suspension.
On 9 August 2021, Ms. Lepchenko was sent a pre-charge notice of an Anti-Doping Rule Violation under Article 2.1 of the Programme (presence of a Prohibited Substance in a Player’s Sample) and was Provisionally Suspended with effect from 19 August 2021. Ms. Lepchenko had (and retains) the right to apply to the Chair of the Independent Tribunal convened to hear her case why the Provisional Suspension should not be imposed (or should be vacated), but has not exercised that right to date.